Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Lemonade Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while Lemonade Inc trades at $46.5 (market cap $3.63B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 3.5× Lemonade Inc's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Lemonade Inc for 27 Days on average.
| HALO | LMND | |
|---|---|---|
Market Cap | $12.58B | $3.63B |
Volume | 2,179,278 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $115.22 | $96.57 |
52-Week Low | $61.63 | $43.91 |
Typical Hold Time | 1 Days | 27 Days |
Enterprise Value | $14.49B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
LMND trades at $46.46, down 0.79% on the day, with a bearish technical signal and key resistance at $48. Revenue growth is strong, rising to $738 million in 2025, but the company remains unprofitable with a net margin of -22.43%. Recent news highlights expansion into new states and AI-driven efficiency gains, targeting EBITDA profitability by late 2026.
The outlook balances high growth potential against persistent losses. Analyst consensus is divided with a $67 price target suggesting upside, but execution risks and competitive pressures remain key concerns. The path to profitability is the critical catalyst for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
